Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 2,185 Cr.
- Current Price ₹ 455
- High / Low ₹ 559 / 264
- Stock P/E
- Book Value ₹ 305
- Dividend Yield 0.00 %
- ROCE 1.80 %
- ROE -1.44 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 30.5%
- Company has a low return on equity of 3.27% over last 3 years.
- Promoters have pledged 48.0% of their holding.
- Promoter holding has decreased over last 3 years: -13.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,407 | |
464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,463 | |
Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -56 |
OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -4% |
2 | 12 | 27 | 29 | 16 | 22 | -60 | |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 96 |
Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 105 |
Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -317 |
Tax % | -70% | 1% | 0% | 0% | 36% | 50% | |
0 | 59 | 115 | 221 | -58 | -22 | -308 | |
EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -64.22 | |
Dividend Payout % | 0% | 22% | 5% | 11% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 3% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -949% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 1% |
3 Years: | -35% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 3% |
Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 |
Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 1,427 |
633 | 538 | 722 | 621 | 1,037 | 1,013 | 985 | |
425 | 466 | 346 | 404 | 383 | 386 | 427 | |
Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,875 |
1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,313 | |
CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 250 |
Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 |
663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 1,310 | |
Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,875 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
49 | 166 | 242 | 155 | -242 | 156 | |
-85 | -113 | -359 | -106 | -243 | -81 | |
68 | -23 | 97 | 92 | 334 | -113 | |
Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 |
Days Payable | 420 | 127 | 132 | 156 | 154 | 142 |
Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 |
Working Capital Days | 107 | 34 | 67 | 118 | 251 | 213 |
ROCE % | 10% | 12% | 15% | -0% | 2% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
24 May - Secretarial Compliance Report for the year ended March 31, 2024.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 22 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
21 May - Investors call to discuss audited financial results for the period ended March 31, 2024.
- Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended March 31, 2024. 21 May
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
20 May - Press release issued by the Company titled: ''''Solara Visakhapatnam facility completes USFDA Inspection with Zero 483 inspectional observations.
Annual reports
Concalls
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Business Segments
It is a global, R&D-focused, pure-play Active Pharmaceutical Ingredients (API) company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. [1]